Media & Press2019-09-17T16:08:49-04:00

    Bexion Pharmaceuticals Announces Database Lock in Phase 1 Trial of BXQ-350

    December 10, 2020|

    FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020               Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome's roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients ... Read More

      Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors

      November 16, 2020|

      FOR IMMEDIATE RELEASE Covington, KY November 16, 2020               Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. Currently, he is President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio (NASDAQ: ... Read More

        Bexion Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation

        September 30, 2020|

        FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More

        All Press